Kimryn Rathmell: A unique national resource that translates basic science discoveries into novel therapies
Kimryn Rathmell shared on X:
“I was delighted to welcome HHS.gov Deputy Secretary Andrea Palm on her visit to NIH. We discussed NCI’s Frederick National Laboratory, a unique national resource that translates basic science discoveries into novel therapies to prevent, diagnosis, and treat cancer, AIDS, and other diseases.
We were joined by NCI’s Dr. Doug Lowy, Dr. Kristin Komschlies, Dr. Rosemarie Aurigemma, Dr. James Doroshow, and others who spoke about Frederick National Laboratory, the RAS Initiative, the Developmental Therapeutics Program, and the NCI Experimental Therapeutics (NExT) Program.”
Source: Kimryn Rathmell/X
Dr. Kimryn Rathmell is a distinguished leader and researcher in the field of kidney cancer. Specializing in the research and treatment of complex and hereditary kidney cancers.
She has held leadership positions with organizations such as the American Society of Clinical Oncology and the American Society for Clinical Investigation, she has been elected to esteemed academies including the Association of American Physicians, the American Academy of Arts and Sciences, and the National Academy of Medicine.
Currently serving as the director of the National Cancer Institute, Dr. Rathmell continues to lead research initiatives and advance the understanding and treatment of kidney cancer, ultimately improving the lives of patients worldwide.
-
ESMO 2024 Congress
September 13-17, 2024
-
ASCO Annual Meeting
May 30 - June 4, 2024
-
Yvonne Award 2024
May 31, 2024
-
OncoThon 2024, Online
Feb. 15, 2024
-
Global Summit on War & Cancer 2023, Online
Dec. 14-16, 2023